Sold as Artane. Every FDA application for this active ingredient: 2 branded and 14 generic.
As of Nov 15, 2026, FDA lists 16 applications for Trihexyphenidyl Hydrochloride (sold as Artane), first approved May 13, 1949, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Trihexyphenidyl HCl | Part D | $2.6M | -8% | 29,936 |
| Comparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's DiseaseParkinson Disease (PD) · safia bano | Not applicable | Recruiting | Sep 9, 2026 |
| Anticholinergic Deprescription in SchizophreniaSchizophrenia, Schizoaffective Disorder · Deepak K. Sarpal, M.D. | Phase 4 | Recruiting | Aug 20, 2024 |
| Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral PalsyPediatric Disorder, Genetic Predisposition · Children's Mercy Hospital Kansas City | Phase 1 | Recruiting | Aug 15, 2024 |
| Accelerating TMS for Cervical DystoniaIsolated Cervical Dystonia · Duke University | Phase 2 | Enrolling by invitation | Mar 25, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA